Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 |
| clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00552396 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma | completed | Phase 1 | 32 | Innate PharmaINDUSTRY | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02723071 | A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 6 | Mar 30, 2016 | clinicaltrials |
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01567475 | The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas((RAD001-R)) | completed | Phase 1 | 21 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT00153933 | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00354926 | Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma | completed | Phase 1 | 67 | Applied Molecular EvolutionINDUSTRY | 1 | Jan 7, 2016 | clinicaltrials |
| NCT00141297 | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer | completed | Phase 1 | 74 | PfizerINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00588328 | The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | completed | Phase 1 | 40 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00001575 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia | completed | Phase 1 / Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00693433 | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01321346 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT01902160 | Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00364676 | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 1 | 67 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Sep 22, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT01435863 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) | completed | Phase 1 | 17 | Solasia Pharma K.K.INDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00689507 | A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | completed | Phase 1 | 48 | Applied Molecular EvolutionINDUSTRY | 1 | Jun 29, 2015 | clinicaltrials |
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL(PCYC-1109-CA) | completed | Phase 1 / Phase 2 | 71 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00426855 | Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) | completed | Phase 1 / Phase 2 | 12 | Peter MoosmannOTHER | 0 | Apr 3, 2015 | clinicaltrials |
| NCT00735930 | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2015 | clinicaltrials |
| NCT00694590 | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 20, 2015 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2016source: clinicaltrials